Article

Cymbalta for Chronic Pain

As reported by the Wall Street Journal, the FDA is seeking advice from a panel of medical experts on whether the antidepressant Cymbalta should be used as a treatment for chronic pain.

As reported by the Wall Street Journal, the FDA is seeking advice from a panel of medical experts on whether the antidepressant Cymbalta should be used as a treatment for chronic pain.

Eli Lilly & Co, the company that markets the drug, is seeking approval for the expanded use as a treatment for chronic pain conditions that would include pain caused by osteoarthritis or low back pain. Currently, the drug is also approved to treat diabetic nerve pain, fibromyalgia, and anxiety.

However, there are safety concerns associated with the drug, including possible liver damage and bleeding risks. The drug will be reviewed Thursday.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
© 2024 MJH Life Sciences

All rights reserved.